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ARTICLE

Clinical epigenomics: genome-wide DNA methylation analysis
for the diagnosis of Mendelian disorders
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Bekim Sadikovic 1,2 ✉, Michael A. Levy1,2, Jennifer Kerkhof1,2, Erfan Aref-Eshghi1,2, Laila Schenkel1,2, Alan Stuart1,2, Haley McConkey1,2,
Peter Henneman3, Andrea Venema3, Charles E. Schwartz4, Roger E. Stevenson4, Steven A. Skinner4, Barbara R. DuPont4,
Robin S. Fletcher4, Tugce B. Balci5,6, Victoria Mok Siu5,6, Jorge L. Granadillo7, Jennefer Masters1,2, Mike Kadour1,2, Michael J. Friez4,
Mieke M. van Haelst3, Marcel M. A. M. Mannens3, Raymond J. Louie4, Jennifer A. Lee4, Matthew L. Tedder4 ✉ and Marielle Alders3 ✉
PURPOSE: We describe the clinical implementation of genome-wide DNA methylation analysis in rare disorders across the EpiSign
diagnostic laboratory network and the assessment of results and clinical impact in the ﬁrst subjects tested.
METHODS: We outline the logistics and data ﬂow between an integrated network of clinical diagnostics laboratories in Europe, the
United States, and Canada. We describe the clinical validation of EpiSign using 211 specimens and assess the test performance and
diagnostic yield in the ﬁrst 207 subjects tested involving two patient subgroups: the targeted cohort (subjects with previous
ambiguous/inconclusive genetic ﬁndings including genetic variants of unknown clinical signiﬁcance) and the screening cohort
(subjects with clinical ﬁndings consistent with hereditary neurodevelopmental syndromes and no previous conclusive genetic
ﬁndings).
RESULTS: Among the 207 subjects tested, 57 (27.6%) were positive for a diagnostic episignature including 48/136 (35.3%) in the
targeted cohort and 8/71 (11.3%) in the screening cohort, with 4/207 (1.9%) remaining inconclusive after EpiSign analysis.
CONCLUSION: This study describes the implementation of diagnostic clinical genomic DNA methylation testing in patients with
rare disorders. It provides strong evidence of clinical utility of EpiSign analysis, including the ability to provide conclusive ﬁndings in
the majority of subjects tested.
Genetics in Medicine (2021) 23:1065–1074; https://doi.org/10.1038/s41436-020-01096-4

INTRODUCTION
Mendelian disorders are estimated to occur at a rate of 40 to 82
per 1,000 live births.1 However, if all congenital anomalies are
considered, approximately 8% of individuals are estimated to have
a genetic disorder before reaching adulthood.2 Clinical presentations in most genetic disorders include developmental delay and
intellectual disability (DD/ID), sometimes in combination with
other features including dysmorphism, neuromuscular phenotypes, and other systemic constellations of syndromes.3 Despite
rapid advances in our understanding of the human genome,
nearly two-thirds of the patients with suspected rare genetic
disorders remain without a conclusive molecular genetic
diagnosis.4
Evolution of genetic testing from single-nucleotide assessment
to clinical exome and genome sequencing, while increasing the
diagnostic yield to an average of 36%,4 has also resulted in a
signiﬁcant increase in ambiguous or uncertain genetic ﬁndings,
referred to as variants of unknown clinical signiﬁcance (VUS).
Despite concerted efforts to standardize guidelines for the
interpretation of sequence variants5 and to deﬁne the functional
evidence for variant classiﬁcation,6 a large proportion of VUS
remain without conclusive clinical interpretation. Also, the understanding of the impact of genetic variation outside of proteincoding DNA sequences is very limited, and as such, the majority of
genetic testing in clinical laboratories is focused on exonic and

short surrounding intronic sequences. Family variant cosegregation studies, in silico prediction algorithms, and gene-speciﬁc
functional studies may help resolve VUS ﬁndings, but in the
majority of cases these are not available, feasible, or conclusive.
One functional consequence of genetic defects in patients with
hereditary neurodevelopmental disorders is the disruption of
genomic DNA methylation.7 DNA methylation is an epigenetic
modiﬁcation, resulting in changes in structural and chemical
properties of the DNA, impacting molecular mechanisms including
chromatin assembly and gene transcription.8 Our group and
others have demonstrated that individuals among a growing
number of rare disorders exhibit DNA methylation “episignatures”
or “EpiSigns” as highly sensitive and speciﬁc DNA methylation
biomarkers.9–22 These genome-wide DNA methylation proﬁles
currently include over 40 rare disorders in association with more
than 60 genes, and can be gene domain, gene level, as well as
protein complex speciﬁc. DNA methylation episignatures are
detectable in peripheral blood and are highly sensitive and
speciﬁc for each disorder. As such, they represent effective
biomarkers for the testing of patients with a broadening range of
neurodevelopmental genetic conditions, as well as a reﬂex
functional test for patients with ambiguous genetic test ﬁndings
or clinical phenotypes.23
Genomic DNA methylation analysis is also adaptable to the
routine analytical processes in clinical laboratories. Cytosine
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methylation is a highly stable analyte, and genome-wide DNA
methylation data can be generated on a microarray platform. In
parallel with episignature screening, genomic DNA methylation
analysis enables concurrent and highly sensitive and speciﬁc
assessment of imprinting disorders24 and fragile X syndrome,25
enabling further test consolidation in this patient population. One
key technical challenge in the clinical setting is data analysis. This
requires the development of large-scale reference DNA methylation databases, including disorder and tissue-speciﬁc reference
data sets and controls, and sophisticated analytical processes
including machine learning algorithms as analytical classiﬁers.
Testing must be performed in a regulated clinically certiﬁed
environment, with adherence to the required quality management procedures, and clinical quality metrics, all under professional clinical oversight.
In this study we describe the implementation and validation of
EpiSign, a clinical genome-wide DNA methylation test for patients
with rare Mendelian disorders, based on the Illumina Inﬁnium
methylation array technology and the EpiSign Knowledge
Database (EKD). We describe the quality metrics and clinical
validation metrics within an integrated network of licensed
academic nonproﬁt clinical laboratories in Europe, Canada, and
the United States. We describe the clinical performance and the
diagnostic yield in subjects tested between initiation of the service
in November 2019 to June 2020. This study demonstrates the
clinical utility of genomic DNA methylation testing in patients with
Mendelian neurodevelopmental disorders.
MATERIALS AND METHODS
Clinical validation and patient cohorts
The validation cohort (Table S1) was designed to clinically validate and
assess quality metrics of the EpiSign test across the EpiSign diagnostic
laboratory network, and consisted of 211 archived peripheral blood DNA
samples including samples with conﬁrmed diagnosis of one of 43 genetic
syndromes included in the EpiSign v2 genome-wide DNA methylation
assay (Table 1), or controls. The genetic variation in these specimens were
classiﬁed as pathogenic or likely pathogenic based on the American
College of Medical Genetics and Genomics (ACMG) guidelines for
interpretation of genomic sequence variants.5 Technical inter and intrarun
replicates were assessed for concordance based on methylation variant
pathogenicity (MVP) score (within 0.05) and clustering analysis. The clinical
testing cohort (Table S2) consists of peripheral blood DNA samples from
207 subjects, referred by physicians based on individual clinical discretion,
who have received clinical EpiSign testing. All subjects provided informed
consent for clinical genetic testing as part of pretest counseling.
DNA methylation analysis was performed using the Illumina Inﬁnium
EPIC bead chip arrays as previously described9 by the clinical testing
laboratories: Greenwood Genetic Center (Greenwood, SC, USA) and
Amsterdam University Medical Center and partner labs (Amsterdam,
Netherlands). Data from validation and clinical testing specimens
(November 2019 and June 2020) were blinded and submitted to the
clinical bioinformatics laboratory (Molecular Diagnostics Laboratory,
London Health Sciences Centre, Western University, London, Canada)
through a secure ﬁle transfer protocol and housed on the hospital clinical
encrypted servers.

DNA methylation data analysis
Analysis of the DNA methylation array data was performed by the clinical
bioinformatics laboratory using Illumina Inﬁnium EPIC arrays. Methylation
data for each sample were compared to the established DNA methylation
episignatures for the 43 disorders (Table 1) which are part of the EpiSign
clinical test. EpiSign analysis utilized the EKD, a clinical database with
>5,000 peripheral blood DNA methylation proﬁles including disorderspeciﬁc reference cohorts and normal (general population samples with
various age and racial backgrounds) controls housed at London Health
Sciences Centre Molecular Diagnostics Laboratory (https://www.lhsc.on.ca/
palm/molecular.html). Individual DNA methylation data for each subject
were compared with the EKD using the support vector machine (SVM)
based classiﬁcation algorithm for EpiSign disorders. Methylation variant
Pathogenicity (MVP) score is generated ranging between 0 and 1,

representing the conﬁdence of prediction for the speciﬁc class the SVM
was trained to detect. Conversion of SVM decision values to these scores
was carried out according to the Platt scaling method.26 Classiﬁcation for a
speciﬁc EpiSign disorder included MVP score assessment with a general
threshold of >0.5 for positive, <0.1 negative, 0.1–0.5 inconclusive or low
conﬁdence, hierarchical clustering and the multidimensional scaling (MDS)
of subject’s methylation data relative to the disorder-speciﬁc EpiSign probe
sets and controls. A detailed description of this analytics protocol was
described previously.9,27

Clinical assessment and reporting
DNA methylation analysis results were clinically veriﬁed by a boardcertiﬁed clinical molecular geneticist at the clinical bioinformatics
laboratory. Result categories include positive (matching an EpiSign
disorder), negative (not matching any EpiSign disorder), and inconclusive
(described in detail in results). The report is then reviewed and veriﬁed by a
board-certiﬁed laboratory professional in the clinical testing laboratory,
and a clinical report describing the EpiSign results (positive, negative, or
inconclusive for a particular episignature) is issued to the requesting
physician.

RESULTS
EpiSign clinical validation
The 211 validation specimens are described in Table S1. Data were
generated at the clinical testing laboratories, anonymized, and
submitted to the clinical bioinformatics laboratory for EpiSign
analysis. EpiSign analysis was concordant with the previous
genetic ﬁndings in 207/211 samples. A positive control cohort
included 143 samples with various genetic disorders with
previously reported DNA episignatures, imprinting and uniparental disomy disorders, and fragile X syndrome. Of these, 139 were
concordant for the expected episignature. The discordant cases
included a subject (Val118) with a previously reported likely
pathogenic variant, KANSL1 (NM_001193466.1): c.297_307del; p.
Gly100Glnfs*6, related to Koolen–de Vries syndrome (KDVS), and
another subject (Val26) with a previously reported likely pathogenic variant, CREBBP (NM_004380.2):c.4480C>A; p.Pro1494Thr,
related to the Rubinstein–Taybi syndrome (RSTS). In the case
Val118 with the KANSL1 likely pathogenic variant, and clinical
features consistent with KDVS, the MVP score for KDVS was zero.
Some individuals carry a duplication harboring part of the KANSL1
gene elsewhere in the genome, which may cause variants in the
duplicated region to be erroneously assigned to the KANSL1 gene.
However, assessment of exome sequencing data, array comparative genomic hybridization (array CGH), and multiplex ligationdependent probe ampliﬁcation (MLPA) analysis showed no
evidence of this this duplication. The MVP score in the second
case,
Val26,
with
CREBBP(NM_004380.2):c.4480C>A,
p.
(Pro1494Thr), for RSTS was zero. Potential mosaicism of the
CREBBP variant was not apparent. The remaining two discordant
cases (Val128 and Val140) both had previously identiﬁed SMARCC2
pathogenic variants. Fifty-six samples were normal reference
controls (NC) and were all concordant. The remaining 12 samples
(other controls in Table S1) included samples with previous
genetic ﬁndings that are currently undetectable by EpiSign
analysis including samples with low-level mosaicism for imprinting
disorders, fragile X female heterozygotes, 16p11del and ARID2
pathogenic variant. There were 10 interrun duplicates (samples
processed in different array batches) and 18 intrarun duplicates
(replicate samples processed in the same batch), and all were
concordant. EpiSign v2 validation included 55 replicates of
samples used in v1 validation and all were concordant.
EpiSign clinical testing
EpiSign analysis includes genetic conditions that exhibit DNA
methylation episignatures as well as the common imprinting
disorders and fragile X (Table 1). A total of 207 subjects were
Genetics in Medicine (2021) 23:1065 – 1074
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Table 1.

Disorders detectable by EpiSign v2.

Disease/disorder

Causative gene(s)/region

New in
EpiSign V2

Validation
cohort positives

ɑ-thalassemia/mental retardation X-linked syndrome
(ATR-X)

ATRX (301404)

No

Autism, susceptibility to, 18 (AUT18)

CHD8 (610528)

Yes

BAFopathies: Cofﬁn–Siris (CSS1–4, and 8) and
Nicolaides–Baraitser (NCBRS) syndromes

ARID1B (135900), ARID1A (614607),
SMARCB1 (614608), SMARCA4
(614609), SMARCC2 (618362),
SMARCA2 (601358)

ARID1A,
SMARCC2

Blepharophimosis intellectual disability syndrome,
SMARCA2 type

SMARCA2 (OMIM not available,
PMID: 32694869)

Yes

2
1

2

Clinical
cohort
positives
4

6

3

28

10

Börjeson–Forssman–Lehmann syndrome (BFLS)

PHF6 (301900)

Yes

Cerebellar ataxia, deafness, and narcolepsy, autosomal
dominant (ADCADN)

DNMT1 (604121)

No

CHARGE syndrome

CHD7 (214800)

No

6

4

Cornelia de Lange syndrome (CdLS)

NIPBL (122470), RAD21 (614701),
SMC3 (610759), SMC1A (300590)

No

11

6

Down syndrome

Trisomy 21 (190685)

No

1

Epileptic encephalopathy, childhood-onset (EEOC)

CHD2 (615369)

Yes

1

Floating Harbor syndrome (FLHS)

SRCAP (136140)

No

Genitopatellar syndrome (GTPTS) and Ohdo
syndrome, SBBYSS variant (SBBYSS)

KAT6B (606170; 603736)

No

3

2

9

2

Helsmoortel–van der Aa syndrome (HVDAS)a

ADNP (615873)

No

Hunter–McAlpine syndrome (HMA)

Chr5q35-qter duplication (601379)

Yes

Immunodeﬁciency–centromeric instability–facial
anomalies syndrome (ICF)b

DNMT3B (242860), CDCA7 (616910),
ZBTB24 (614069), HELLS (616911)

Yes

Kabuki syndrome

KMT2D (147920), KDM6A (300867)

KDM6A

12

5

Kleefstra syndrome

EHMT1 (610253)

Yes

2

2

Koolen–de Vries syndrome (KDVS)

KANSL1 (610443)

Yes

5

Mental retardation, autosomal dominant 23 (MRD23)

SETD5 (615761)

Yes

4

Mental retardation, autosomal dominant 51 (MRD51)

KMT5B (617788)

Yes

Mental retardation, X-linked 93 (MRD93)

BRWD3 (300659)

Yes

Mental retardation, X-linked 97 (MRD97)

ZNF711 (300803)

Yes

Mental retardation, X-linked syndromic, Nascimentotype (MRXSN)

UBE2A (300860)

Yes

Mental retardation, X-linked, Snyder–Robinson type
(MRXSSR)

SMS (309583)

Yes

Mental retardation, X-linked, syndromic, Claes–Jensen
syndrome (MRXSCJ)

KDM5C (300534)

No

PCR2 complex (Weaver (WVS) and Cohen–Gibson
(COGIS)

EZH2 (277590), EED (617561)

Yes

Rahman syndrome (RMNS)

HIST1H1E (617537)

Yes

Rubinstein–Taybi syndrome (RSTS)

CREBBP (180849), EP300 (613684)

Yes

1

1
1

1
1
6

1

2

3

SETD1B-related syndrome

SETD1B (619000)

Yes

Sotos syndrome

NSD1 (117500)

No

8

1
4

Tatton–Brown–Rahman syndrome (TBRS)

DNMT3A (615879)

Yes

1

1
2

Wiedemann–Steiner syndrome (WDSTS)

KMT2A (605130)

Yes

3

Williams–Beuren deletion syndrome (WBS) and
Williams–Beuren regions duplication syndrome
(Dup7)c

7q11.23 deletion (194050)/
duplication (609757)

No

2

Wolf–Hirschhorn syndrome (WHS)

Chr4p16.13 deletion (194190)

Yes

Fragile X syndrome (FXS)

TNR/FMR1 (300624)

No

Mental retardation, FRA12A type

TNR/DIP2B (136630)

No

Genetics in Medicine (2021) 23:1065 – 1074
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Table 1 continued
Disease/disorder

Causative gene(s)/region

New in
EpiSign V2

Validation
cohort positives

Angelman syndrome (AS)

ID/UBE3A (105830)

No

6
3

Prader–Willi syndrome

ID/15q11 (SNRPN, NDN) (176270)

No

Silver–Russell syndrome 1 (SRS1)

ID/11p15.5 (180860)

No

5

Beckwith–Wiedemann syndrome (BWS)

ID/11p15 (ICR1, KCNQ1OT1,
CDKN1C) (130650)

No

4

Silver–Russell syndrome 2 (SRS2)

ID/7p11.2 (180860)

No

Temple syndrome

ID/14q32 (616222)

No

Kagami–Ogatta syndrome (KOS)

ID/14q32 (608149)

No

Clinical
cohort
positives
1
1

2

OMIM number listed in parentheses adjacent to disorder name. The following list of genes have been classiﬁed as having reduced sensitivity and more
moderate signatures based on signature strength, limited reference cohort size, or types of variants that have been tested: CHD8, PHF6, DNMT3B, CDCA7,
ZBTB24, HELLS, SETD5, KMT5B, BRWD3, ZNF711, KAT6B, SMS, DNMT3A.
ID imprinting disorder, TNR trinucleotide repeat disorder.
a
ADNP has two distinct signatures depending on where in the gene the variant occurs. HVDAS_T signature includes variants that occupy the N- and Cterminus of the gene and HVDAS_C includes variants in the central region of the gene including the nuclear localization signal of the protein.
b
ICF1 exhibits one signature while ICF 2, 3, and 4 exhibit a separate, common signature.
c
These two deletion/duplication syndromes exhibit symmetrical increased/decreased DNA methylation signatures, respectively.

tested by EpiSign analysis and reported in the period between
September 2019 and June 2020. Of these, 57 specimens were
positive for an episignature, 146 were negative, and 4 were
inconclusive (Table S3). Of the 207 subjects, a total of 136 patient
samples had a previous VUS ﬁnding, and of these, 48 (35.3%) had
DNA methylation proﬁles positive for one of the EpiSigns. Most of
the positive cases had robust DNA methylation proﬁles (MVP
scores >0.9 with unambiguous MDS and clustering analysis) with
some positive cases showing moderate, but positive proﬁles
(reduced but positive MVP score, or closer to borderline MDS
clustering). Eighty-six cases had no evidence of a DNA methylation
episignature. The remaining two VUS cases were inconclusive.
Figure 1 shows examples of MVP score plots for Cornelia de
Lange and Sotos syndromes. Figure S1 shows the representative
genomic loci along with reference control and positive DNA
methylation proﬁles for imprinting and fragile X disorders listed in
Table 1. For specimens that screen positive for a speciﬁc MVP
score, hierarchical clustering and multidimensional scaling are
performed. Figure 2 shows data for two subjects with VUS in
SMC1A, the causative gene for Cornelia de Lange syndrome (CdLS)
type 2, SMC1A:c.598A>C, p.(Lys200Gln) and SMC1A:c.1280A>G,
p.(Glu427Gly). The SMC1A:c.598A>C, p.(Lys200Gln) variant was
reclassiﬁed as likely pathogenic, ACMG category 2, and the SMC1A:
c.1280A>G, p.(Glu427Gly) variant did not show evidence of
pathogenicity based on the current reference episignatures. Other
examples depicted in Fig. 3 show data from two subjects with VUS
in NSD1, the causative gene for Sotos syndrome type 1, NSD1:
c.4982G>C, p.(Cys1661Ser) and NSD1:c.3331G>T, p.Asp1111Tyr.
The NSD1:c.4982G>C, p.(Cys1661Ser) was reclassiﬁed to likely
pathogenic, ACMG category 2, while NSD1:c.3331G>T,
p.Asp1111Tyr, which clusters with controls, showed no evidence
of pathogenicity. Similar analysis is performed for all subjects
tested with ﬁndings summarized in Table S3.
One of the four inconclusive clinical testing cases, Clin77, had a
ARID2:c.988_1008del, p.(Leu330_Gly336del) VUS. MVP score for
BAFopathy using the EpiSign v1 was slightly elevated (0.2) but
below the established 0.5 cutoff and above the 0.1 cutoff for
reference normal controls. The updated EpiSign v2 reanalysis
showed no evidence of the elevated BAFopathy score; however,
MRD23 score remained elevated. MDS proﬁle showed clustering
between BAFopathy cohort and controls (Figure S2). The current

BAFopathy episignature is trained on positive cases with
pathogenic variants in ARID1B, ARID1A, SMARCB1, SMARCA2, and
SMARCA4. Since BAF complex–associated ARID2 positive references are not represented, it was not possible to conﬁdently rule
in/out a BAFopathy episignature. Case Clin203 had a previously
identiﬁed ADNP:c.46C>G, p.(Arg16Gly) VUS. The ADNP gene has
two distinct EpiSigns11 as a result of truncating variants in two
distinct protein domains; the 5’ being deﬁned by the variants
ranging from c.56 to c.1287. The MVP score for this subject was
0.03, which is within the normal range, but MVP scores for all other
conditions were zero. Due to the strong hypomethylation
observed with this episignature, MDS analysis clearly separates
the reference from the positive cohort, and this sample plots
between the two (Figure S2). In lieu of these ﬁndings and because
the variant lies outside of the established EpiSign domain, the
result was reported as inconclusive. For case Clin120, the MVP
scores were within the expected reference range but showed
slight elevation for MRX97 (0.02) (Figure S2). Although this value is
within reference control limits, the currently deﬁned episignature
for MRX97 is mild and derived from a limited positive reference
cohort. Since this subject’s phenotype had a partial overlap with
MRX97 the result was reported as inconclusive. The ﬁnal case,
Clin202, was referred because of clinical features consistent with
BAFopathy disorder and no variants identiﬁed in BAF complex
genes. This sample clustered between BAFopathy and the control
samples by the MDS analysis (Figure S2). Although the MVP score
was within the normal reference range for BAFopathy and all
other EpiSign disorders, as in case Clin77, and we could not rule
out involvement of other yet unmapped BAF complex genes.
Notable clinical cases
While one use of EpiSign is to help resolve VUS, there are
scenarios where a DNA methylation episignature is the only
molecular diagnostic ﬁnding. Case Clin136 was referred for
EpiSign analysis due to clinical features consistent with ATRXrelated syndrome. However, previous genetic testing of this
individual did not identify any alterations in the ATRX, using
targeted and exome sequencing. In contrast, EpiSign analysis
conclusively conﬁrmed presence of a speciﬁc ATRX-speciﬁc DNA
methylation signature (Fig. 4). Hence, for this subject, DNA
Genetics in Medicine (2021) 23:1065 – 1074
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Fig. 1 A multiclass supervised classiﬁcation system. This classiﬁcation system, referred to as a methylation variant pathogenicity (MVP) score,
can classify samples using the 43 episignatures in EpiSign v2. Shown here are examples using the Cornelia de Lange syndrome (CdLS)
signature (top) and Sotos signature (bottom), applied to over 1,500 samples from subjects with various neurodevelopmental syndromes or
from healthy controls. In each case, samples from the respective syndrome all have high scores while samples from other syndromes and
controls all have low scores, demonstrating the sensitivity and speciﬁcity of the classiﬁer. The likely pathogenic variants described in Fig. 2
(CdLS) and 3 (Sotos) are shown here larger and in red.

methylation proﬁling remains the only molecular diagnosis
explaining their clinical presentation.
A similar scenario with a different outcome involves subject
Clin6 who was referred for EpiSign analysis as a result of negative
molecular sequencing (CHD7 and SEMA3E), negative microarray,
and negative exome analysis with the phenotype strongly
suggestive of CHARGE syndrome. EpiSign analysis identiﬁed a
DNA methylation proﬁle speciﬁc for CHD7, consistent with the
clinical diagnosis (Fig. 4). As a result, follow-up molecular studies
identiﬁed the causative deep intronic variant in CHD7 and
conﬁrmed the molecular diagnosis. Details of this case resulting
from extensive genomic evaluation by the Undiagnosed Diseases
Network (https://undiagnosed.hms.harvard.edu/) are described in
a separate manuscript in preparation. Hence, EpiSign analysis
provided the necessary evidence for a more in-depth and focused
molecular analysis, ultimately leading to the deﬁnitive molecular
genetic diagnosis.
Case Clin187 highlights an example where extensive molecular
genetic testing was performed without a molecular diagnosis,
referred to as a diagnostic odyssey. Findings included exome
sequencing with PTCHD1:c.605G>A (p.Arg202Gln) VUS, maternal;
VPS13B:c.1520A>G (p.Asn507Ser) VUS, paternal; LAMC3:c.4415G>A
(p.Arg1472Gln), maternal; EZH2:c.2110+6T>G VUS, maternal; and
normal ﬁndings for: FMR1, MECP2, SNP 6.0 microarray, NSD1
(sequencing and MLPA), extensive biochemical workup, and Xinactivation studies. However, EpiSign analysis showed an
episignature associated with DNMT3A, the gene involved in
Tatton–Brown–Rahman syndrome (Fig. 4). Follow up sequencing
of the DNMT3A gene revealed a missense likely pathogenic variant
DNMT3A:c.2146G>A (p.Val716Ile). As an infant, the patient met
motor and speech milestones but regressed at 18 months, losing
speech, attentiveness, and responsiveness to directions. Now at
age 17 years, she has overgrowth (all growth parameters greater
Genetics in Medicine (2021) 23:1065 – 1074

than the 97th centile), limited speech, echolalia, mild intellectual
disability, and autism spectrum disorder.
DISCUSSION
This paper describes the implementation of genome-wide DNA
methylation analysis in clinical testing of individuals with rare
genetic disorders. It represents a major milestone in molecular
diagnostics as it advances clinical genetic testing beyond
assessment of the DNA nucleotide sequence, or genomics, to
clinical epigenomics. While targeted molecular assays for assessment of DNA methylation defects of imprinting disorders28,29 and
fragile X syndrome30 have been around for decades, EpiSign
enables simultaneous assessment for these, as well as a rapidly
expanding number of genetic neurodevelopmental disorders
exhibiting DNA methylation episignatures.
Clinical impact
The primary clinical utility of EpiSign analysis is the assessment
and reclassiﬁcation of VUS in genes with existing episignatures,15
and the assessment of genetically unsolved individuals with
suspected hereditary conditions.14 While this clinical utility has
been described in a research setting in targeted patient cohorts,
this study focuses on the assessment of the impact of genomewide DNA methylation analysis in a clinical setting in a prospective
unselected patient population. The majority of the subjects tested
in the clinical cohort (136; 65.7%) had previously identiﬁed genetic
VUS, and of these, 134 (98.5%) received a conclusive EpiSign
report (positive or negative), of which 48 (35.3%) showed a
distinct EpiSign. For the 86 (63.2%) VUS cases with negative
EpiSign results, lack of an episignature is considered strong
evidence for rule out of these disorders. However, due to the
possibility of the existence of additional/alternate yet unmapped
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Fig. 2 DNA methylation (EpiSign) analysis of peripheral blood from two subjects with variants of unknown clinical signiﬁcance (VUS) in
SMC1A, the causative gene for Cornelia de Lange syndrome (CdLS) type 2. The variants are SMC1A:c.598A>C, p.(Lys200Gln) (labeled red and
clustering with CdLS samples) and SMC1A:c.1280A>G, p.(Glu427Gly) (labeled red and clustering with control samples). (a) Hierarchical
clustering and (b) multidimensional scaling plot of subjects with a conﬁrmed CdLS episignature, controls, and the VUS under investigation.
The SMC1A:c.598A>C VUS clustering with the CdLS samples indicates it has a DNA methylation signature similar to that seen in other CdLS
samples and suggesting that the variant is pathogenic, while SMC1A:c.1280A>G is likely benign. (c) Methylation variant pathogenicity (MVP)
score, a multiclass supervised classiﬁcation system capable of discerning between the 43 different episignatures in EpiSign V2, was applied to
the SMC1A:c.598A>C likely pathogenic variant (top) and the SMC1A:c.1280A>G likely benign variant (bottom). This classiﬁcation system
generates a probability score for each episignature, with a score near 1 indicating that the sample has an episignature similar to the reference
episignature.

episignatures in these genes, as has been demonstrated in ADNP11
and SMARCA2,31 we currently stop short of fully ruling out
pathogenicity. Only 2 (1.5%) VUS cases remained unclassiﬁed.
These ﬁndings represent a signiﬁcant advancement in clinical
variant assessment over currently available methodologies. While
alternative approaches for classiﬁcation of VUS exist, including
functional and family segregation studies, these are not always
available, feasible, or conclusive.32 EpiSign analysis is less
susceptible to those limitations as it assesses the same tissue
(patient’s peripheral DNA) used for sequence analysis, and it
generally does not require assessment of other family members.
From a patient, family, and clinical management perspective,

providing the patient and care team with a rapid diagnosis
relating to the functional impact of the genetic condition, which
for a microarray-based test can be achieved within 1–2 weeks,
may be most beneﬁcial to decision-making.
Of the remaining 71 subjects without the previously identiﬁed
genetic ﬁndings, 8 subjects (11.3%) had a positive EpiSign result,
demonstrating evidence for the clinical utility of EpiSign analysis
in a broader patient population. Given that these subjects already
had varying degrees of targeted genetic investigations completed
with no conclusive ﬁndings, some of the EpiSign disorders had
effectively been ruled out already. These ﬁndings taken together
suggest there may be a health systems value proposition of
Genetics in Medicine (2021) 23:1065 – 1074
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Fig. 3 DNA methylation (EpiSign) analysis of peripheral blood from two subjects with variants of unknown clinical signiﬁcance (VUS) in
NSD1, the causative gene for Sotos syndrome type 1. The variants are NSD1:c.4982G>C,p.Cys1661Ser) (labeled red and clustering with NSD1
samples) and NSD1:c.3331G>T,p.Asp1111Tyr (labeled red and clustering with control samples). (a) Hierarchical clustering and (b)
multidimensional scaling plot of subjects with a conﬁrmed Sotos episignature, controls, and the VUS under investigation. The NSD1:
c.4982G>C VUS clustering with the Sotos samples indicates it has a DNA methylation signature similar to that seen in other Sotos samples and
suggesting that the variant is pathogenic, while NSD1:c.3331G>T is likely benign. (c) Methylation variant pathogenicity (MVP) score, a
multiclass supervised classiﬁcation system capable of discerning between the 43 different episignatures in EpiSign v2, was applied to the
NSD1:c.4982G>C likely pathogenic variant (top) and the NSD1:c.3331G>T likely benign variant (bottom). This classiﬁcation system generates a
probability score for each episignature, with a score near 1 indicating that the sample has an episignature similar to the reference
episignature.

instigating use of EpiSign earlier in the diagnostic journey of
individuals with rare disorders.
Application of this technology to the broader patient populations will depend on the rate of discovery of gene and disorderspeciﬁc episignatures. As a corollary, implementation of chromosomal microarrays as a ﬁrst-tier diagnostic test was primarily
contingent upon increased diagnostic yield compared with
karyotyping (from 5% to 10–15%) resulting from years of research
and discovery of novel microdeletion and duplication syndromes,
often involving large clinical databases and registries.33,34
Similarly, there are now major efforts underway to assess the
clinical utility and the health systems impact, and to accelerate the
rate of episignature discovery including a national-scale trial
Genetics in Medicine (2021) 23:1065 – 1074

(“Beyond Genomics: Assessing the Improvement in Diagnosis of
Rare Diseases using Clinical Epigenomics in Canada [EpiSignCAN]”), which will compare the impact of DNA methylation
analysis as a ﬁrst-line versus a second-line test in 4,000 individuals
with suspected rare disorders while assessing EpiSigns in 100
additional genetic conditions (https://www.genomecanada.ca/en/
beyond-genomics-assessing-improvement-diagnosis-rarediseases-using-clinical-epigenomics-canada).
The clinical cases presented in detail highlight some important
implications of this technology. One is the sequential use of
EpiSign analysis with genetic testing. While using EpiSign to
investigate individuals with VUS or related clinical presentations
provides demonstrated value, EpiSign can also uncover genetic
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Fig. 4 Clinical case EpiSign assignment. Assessment of the notable clinical cases. (a) Principal component analysis (PCA) plots for Clin136 (no
genetic variant identiﬁed), Clin6 (no genetic variant identiﬁed), and Clin187 (DNMT3A:c.2146G>A [p.Val716Ile]). (b) Corresponding methylation
variant pathogenicity (MVP) scores for the notable clinical cases. Both PCA plots and MVP scores provide conclusive evidence for EpiSign
classiﬁcation of these clinical cases.

disorders that were not initially suspected. We have previously
demonstrated an incremental diagnostic yield of approximately
3% in patients with prior extensive genomic testing but without a
genetic diagnosis.9,14 Existence of a speciﬁc DNA methylation
pattern can guide the molecular assessment, and in some cases
resolve complex diagnostic odysseys, which can have a huge
impact on patient care and the related health systems costs.35,36
Clinical service delivery
EpiSign testing is performed using an integrated model involving
primary labs performing and reporting test results with informatics and databasing centralized in the tertiary clinical bioinformatics laboratory, similar to the ﬁeld of noninvasive prenatal
testing for aneuploidy.37 The key beneﬁts of this model involve
standardization and coordinated quality management and quality
assessment procedures, ensuring consistency across the different
provider laboratories, which is critical given the inherent nature
and complexity of this analysis. This also allows for more rapid
expansion of reference DNA methylation databases and facilitates
continuous optimization of the underpinning analytical algorithms. As the EKD expands, the reference machine
learning–derived algorithms that form the basis of individual
EpiSigns become more sensitive and speciﬁc,9 enabling regular
and documented updates to the analytical software, with the
appropriate quality metrics and quality control documentation
and version controls.
Limitations
There are a number of challenges related to introducing a
diagnostic modality to the clinical laboratory, and EpiSign is not an
exception. Unlike DNA sequencing, DNA methylation analysis is

limited to peripheral blood where large reference databases are
available. Other factors including age, sex, and environmental
exposures can also impact the analysis and need to be accounted
for in analytical processes.38,39
DNA methylation episignatures can be susceptible to technical
variation such as sample processing data batch effects, as well as
biological parameters such as mosaicism. The validation cohort
included a number of low-level mosaic imprinting disorders that
may not be readily detectable by the EpiSign assay. In our
previous work we were able to detect mosaicism in imprinting
disorders24 and fragile X,25 at levels >20%, but due to normal
control variability (Figure S1), this is currently not routinely
possible for samples with lower-level mosaicism. Mosaicism is
also a limitation for detection of other EpiSigns, and may provide
an explanation for some of the discordant samples. We have
previously demonstrated that total gene dosage dilutes the
intensity of the EpiSign signal, as in heterozygous females in the Xlinked KDM5C-related Claes–Jensen syndrome;16 however, here, as
a result of having a reference cohort we were able to derive a
speciﬁc and sensitive MVP score for heterozygous females. In
addition to mosaicism, a possible reason for nonconcordance in a
laboratory setting could be sample mix up. Alternatively,
discordance of sample Val26 with CREBBP:c.4480C>A, p.
(Pro1494Thr) may be explained by the variant not actually being
pathogenic, or an existence of a yet unmapped episignature in
this gene.
Other biologically based limitations of EpiSign analysis can be
highlighted by the four inconclusive samples from the clinical
testing cohort. The current BAFopathy episignature is trained on
positive cases with pathogenic variants in ARID1B, ARID1A,
SMARCB1, SMARCA2, and SMARCA4.17 Hence, it is not possible to
completely rule out pathogenicity of a variant of another BAF
Genetics in Medicine (2021) 23:1065 – 1074
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complex gene as for the case with the ARID2 variant. An
alternative scenario is highlighted by ADNP, which was the ﬁrst
gene in which the existence of multiple, domain-speciﬁc
episignatures was described.11 Although majority of the EpiSign
genes currently have a single common episignature mapped,
assessment of pathogenicity of variants outside the established
reference range and variant type warrants caution, as in the
inconclusive case Clin203.
An overarching challenge with this technology is the rarity of
Mendelian disorders. While the population prevalence of rare
diseases is 3.5–5.9%, equating to 263–446 million persons affected
globally, given that this number encompasses >5,000 diseases, the
prevalence of rare disorders ranges between 1–5 per 10,000 and <1/
1,000, 000.40 Generation of EpiSigns requires cohorts of subjects
with gene-speciﬁc pathogenic variants, which is currently possible
for the more prevalent disorders. Also, as many of the episignatures
are mild in scale, the size of the reference cohort is directly
correlated to the level of sensitivity of the assay. Hence, occasionally,
as in the case Clin120 for example, the results may be inconclusive.
While the recommendations for application of the functional
evidence in genetic testing now exist,6 there are currently no
speciﬁc guidelines for the clinical interpretation of genomic DNA
methylation ﬁndings. EpiSign employs the use of DNA methylation
data as a surrogate for evidence of the underpinning genetic defects
that may or may not be detectable using the current molecular
testing modalities. Another challenge is that our current knowledge
of the full scope of these genetically associated epiphenotypes is
limited. Hence, while on the one hand a conﬁrmation of a related
episignature in a patient with a genetic VUS may be considered a
molecular diagnosis, a negative result in a patient with or without a
known genetic variant is not an absolute rule-out and the analysis
would be considered a molecular screen. A more complex challenge
is a conﬁrmation of an episignature in absence of a detectable
genetic variation, in particular when it is observed in a patient with a
matching clinical diagnosis. In this case EpiSign is the standalone
molecular diagnosis.
Conclusion
This study describes the implementation of clinical genomic DNA
methylation testing in patients with rare disorders. It demonstrates strong evidence of clinical utility, including the ability to
provide conclusive diagnoses in a signiﬁcant proportion of
subjects tested. It also highlights the limitations and challenges
with implementation and use of this diagnostic modality. As this
technology evolves, the number and type of rare disorders with
EpiSigns is going to expand, increasing its clinical utility. While the
current clinical use of EpiSign focuses on cases with VUS, and very
speciﬁc clinical presentations, expanding clinical utility of this test
may justify its application earlier in the diagnostic journey, in a
broader patient population. Larger-scale studies, such as EpiSignCAN, are necessary to assess the diagnostic yield and health
system impact as either a ﬁrst-line test or in unresolved cases
post–genomic assessment. Finally, the development of clinical
guidelines for use and application of clinical epigenomic
technologies is warranted.
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